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Abstract Multiple system atrophy (MSA) is a progres-
sive late onset neurodegenerative a-synucleinopathy with
unclear pathogenesis. Recent genetic and pathological
studies support a central role of a-synuclein (aSYN) in
MSA pathogenesis. Oligodendroglial cytoplasmic inclu-
sions of ﬁbrillar aSYN and dysfunction of the ubiquitin–
proteasome system are suggestive of proteolytic stress in
this disorder. To address the possible pathogenic role of
oligodendroglial aSYN accumulation and proteolytic fail-
ure in MSA we applied systemic proteasome inhibition
(PSI) in transgenic mice with oligodendroglial human
aSYN expression and determined the presence of MSA-
like neurodegeneration in this model as compared to wild-
type mice. PSI induced open ﬁeld motor disability in
transgenic aSYN mice but not in wild-type mice. The
motor phenotype corresponded to progressive and selective
neuronal loss in the striatonigral and olivopontocerebellar
systems of PSI-treated transgenic aSYN mice. In contrast
no neurodegeneration was detected in PSI-treated wild-
type controls. PSI treatment of transgenic aSYN mice was
associated with signiﬁcant ultrastructural alterations
including accumulation of ﬁbrillar human aSYN in the
cytoplasm of oligodendroglia, which resulted in myelin
disruption and demyelination characterized by increased
g-ratio. The oligodendroglial and myelin pathology was
accompanied by axonal degeneration evidenced by signs of
mitochondrial stress and dysfunctional axonal transport in
the affected neurites. In summary, we provide new evi-
dence supporting a primary role of proteolytic failure and
suggesting a neurodegenerative pathomechanism related to
disturbed oligodendroglial/myelin trophic support in the
pathogenesis of MSA.
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Introduction
Multiple system atrophy (MSA) is a sporadic neurodegen-
erative disorder clinically characterized by parkinsonism,
cerebellar, autonomic, and pyramidal dysfunction [37]. The
pathogenesis of the disease remains largely unknown. The
neuropathology includes various degrees of striatonigral
degeneration (SND) and olivopontocerebellar atrophy
(OPCA) which deﬁne the substrate of atypical parkinson-
ism and ataxia in MSA. a-Synuclein (aSYN)-positive
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brain in neurons (like in other a-synucleinopathies) and
uniquely in oligodendrocytes (named glial cytoplasmic
inclusions (GCIs))andmay contribute to the MSA pattern of
neurodegeneration [8, 12, 44]. A major role of aSYN in the
pathogenesis of MSA has also been suggested by genome-
wide association (GWA) studies revealing association of
polymorphisms within the aSYN gene (SNCA) with
increased MSA risk [1, 35]. Furthermore, recent evidence
indicates that dysfunction of the ubiquitin–proteasome sys-
tem (UPS) is a common pathogenic mechanism in
a-synucleinopathies including Parkinson’s disease (PD),
dementia with Lewy bodies, and MSA [5]. Speciﬁcally, in
MSA brain tissue reduced immunoreactivity for the 20S-a
subunit of the core proteasome complex has been shown in
dopaminergic nigral neurons [5]. The 20S proteasome sub-
unit gene expression has been found to be downregulated in
the pons of MSA patients [20]. These data suggest that pro-
teolytic stress in MSA might result from impaired
degradation (proteasome dysfunction) and excess aberrant
accumulationofaSYNspeciﬁcallyaffectingoligodendroglia
by yet unknown mechanisms, which eventually lead to
selective and wide-spread multisystem neurodegeneration.
Transgenic overexpression of human aSYN (haSYN)
under the control of oligodendroglial promoters has been
classically introduced to model MSA-like glial inclusions
[40]. Transgenic mice with oligodendroglial overexpres-
sion of haSYN under the control of proteolipid protein
(PLP) promoter feature GCIs of hyperphosphorylated
insoluble haSYN with asymptomatic early neurodegener-
ation and microgliosis [14, 39, 41]. We sought to enhance
proteolytic stress through systemic proteasome inhibition
inthePLP-haSYNtransgenicmouse[14]anddeﬁnepossible
pathogenic mechanisms related to MSA-like neurodegener-
ation. For the ﬁrst time we show ultrastructural mechanisms
of neurodegeneration related to PSI-accelerated oligoden-
droglial aSYN accumulation associated with myelin
disruption and axonal degeneration providing novel insights
into MSA pathogenesis.
Materials and methods
Animals and treatment
The generation and characterization of the PLP-haSYN
mice were previously described [14]. Homozygous trans-
genic PLP-haSYN mice were obtained from Prof. Philipp
Kahle (Tu ¨bingen, Germany) and further bred and main-
tained in a temperature-controlled speciﬁc pathogen free
(SPF) room under 12-h light/dark cycle with free access to
food and water at the Animal Facility of Innsbruck Medical
University. All mice were genotyped by tail clip using PCR
for human aSYN with the following primers, fwd: 50-ATG
GAT GTA TTC ATG AAA GG-30; rev: 50-TTA GGC TTC
AGG TTC GTA G-30 giving a product size of 450 bp. The
oligodendroglial aSYN overexpression was determined by
20,30-cyclic nucleotide 30-phosphodiesterase (CNPase)/
aSYN double immunoﬂuorescence as previously shown
[14, 41]. All experiments were performed according to
Austrian law and with permission from the Federal Min-
istry of Science and Research, Austria. All efforts were
made to minimize the number of animals used and their
suffering.
Transgenic mice over 12 months of age and age-mat-
ched wild-type controls of the background strain C57Bl/6
were randomized into two treatment groups receiving
either proteasome inhibitor (PSI) or vehicle. The PSI
groups received proteasome inhibitor I (Z-Ile-Glu(OtBu)-
Ala-Leu-CHO), a cell-permeable reversible inhibitor of the
chymotrypsin-like activity of the 20S proteasome, provided
in 50 mM stock solution in DMSO (Calbiochem, La Jolla,
CA). PSI was applied subcutaneously every other day over
a period of 2 weeks at a concentration of 5 mg per kilo
body weight per day in 1.7 % DMSO in saline as based on
previous protocols and data [4, 13, 19, 22, 34, 36, 46]. The
vehicle-treated groups received 1.7 % DMSO in saline
according to the same time schedule. Subgroups were
behaviorally tested and killed 2 and 12 weeks after the ﬁrst
PSI/vehicle injection according to the following protocols.
Chemicals, sera, and antibodies
Paraformaldehyde, osmium tetroxide, uranyl acetate, and
pioloform were obtained from Agar Scientiﬁc (Stansted,
UK). EM grade glutaraldehyde was purchased from Poly-
sciences (Warrington, PA). Thiopental was from Sandoz
(Kundl, Austria). Lead(II) citrate was from Merck
(Darmstadt, Germany), picric acid from Fluka (Buchs,
Switzerland). Normal goat serum was from Bender
(Vienna, Austria), bovine serum albumin from Serva
(Heidelberg, Germany). Biotinylated antibodies (horse
anti-mouse IgG, goat anti-rat IgG) and Elite avidin–bio-
tinylated horseradish peroxidase complex were from
Vector Laboratories (Burlingame, CA). Gold-conjugated
immunoglobulins were from British BioCell (Cardiff, UK).
The nanogold
-conjugated Fab0 fragments and the
HQ Silver
TM Enhancement Kit were from Nanoprobes
(Yaphank NY, USA). All remaining chemicals were from
Sigma-Aldrich (Vienna, Austria).
The monoclonal anti-DARPP-32 (1:20,000) was a gen-
erous gift from Prof. H. Hemmings (New York, USA),
monoclonal anti-TH (1:500) and monoclonal anti-CNPase
(clone 11-5B, 1:100) were from Sigma (St. Louis, USA),
monoclonal anti-human-a-synuclein (15G7, aa 116-131,
1:10) was generously provided by PJ Kahle (Tu ¨bingen,
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15-123, 1:50) was from BD Transduction Laboratories
(Lexington, KY). Monoclonal anti-mouse glial ﬁbrillary
acidic protein (GFAP, 1:100) was from Roche (Vienna,
Austria) and monoclonal anti-mouse CD11b (1:150) was
from Serotec (Oxford, UK). All antibodies were applied
successfully in immunohistochemistry before [15, 30, 32,
38]. The speciﬁcity of the immunostainings was veriﬁed in
the current study by omitting primary antibodies and
incubating sections with the full set of secondary
antibodies.
For immunoblotting polyclonal anti-ubiquitin antibody
was purchased from Abcam (Cambridge, UK, 1:2,000),
polyclonal anti-LC3B antibody from Cell Signaling Tech-
nology (Beverly, MA, 1:1,000), and monoclonal anti-actin
antibody from BD Transduction Laboratories (Franklin
Lakes, NJ, 1:10,000).
Tissue processing
For morphological analysis animals were perfusion ﬁxed
under thiopental anesthesia (12 mg/100 g body weight,
intraperitoneally; either on day 15 or day 85 after the ﬁrst
PSI/vehicle injection) with 10 ml phosphate buffered saline
(PBS; 25 mM, 0.9 % NaCl, pH 7.4) followed by chilled
ﬁxative in PBS (buffer conditions are given below for the
different techniques used). Brains were rapidly removed
from skulls, postﬁxed overnight in the same ﬁxative at
4 C, and washed in 0.1 M PBS containing 0.05 % sodium
azide at 4 C.
Immunohistochemistry for light microscopy
Brains were perfusion ﬁxed with 4 % paraformaldehyde in
PBS. Following ﬁxation and dissection, they were cryo-
protected in 25 % sucrose in PBS, quickly frozen by
immersion in cold (–50 C) isopentane, and stored at
–70 C. Frozen brains were sliced serially at 40 lm using a
cryostat (Leica, Nussloch, Germany). One series of sec-
tions per animal was mounted on slides and underwent
cresyl violet (CV) staining to deﬁne the borders and
determine the numbers of neurons in the inferior olivary
complex, pontine nuclei, and deep cerebellar nuclei. Series
of brain sections underwent immunohistochemical staining
according to a standard immunoperoxidase protocol for
free-ﬂoating sections. Shortly thereafter, endogenous per-
oxidase activity was quenched in 0.3 % H2O2 in PBS.
After 5 % normal serum blocking in PBS containing 1 %
bovine serum albumin (BSA) sections were incubated with
the primary antibody overnight at 4 C, followed by
incubation in biotinylated secondary antibody (1:500 for
1 h) at room temperature. After incubation in Vectastain
ABC reagent the immunohistochemical reaction was
developed with 3,30-diaminobenzidine (DAB) and sections
were mounted onto gelatine-coated slides, dehydrated, and
coverslipped with Entellan.
Ultrastructural analysis
Brains were perfusion ﬁxed with phosphate buffer (PB;
0.1 M, pH 7.4) containing 2 % formaldehyde and 2.5 %
glutaraldehyde. Tissue blocks from the substantia nigra,
cerebellum, and brain stem were dissected, and coronal
sections were sliced at 60 lm with a Vibroslicer
(VT1000S; Leica Microsystems, Vienna, Austria). Sections
were treated with 2 % osmium tetroxide in PB and
embedded in epoxy resin (Durcupan
 ACM Fluca). Serial
ultrathin sections (70–80 nm) were collected on formvar-
coated copper slot grids and contrasted by means of uranyl
acetate and lead citrate. Sections were examined in a Phi-
lips CM120 transmission electron microscope (TEM),
equipped with a Morada CCD camera (Soft Imaging Sys-
tems, Muenster, Germany). Whole images were level-
adjusted, sharpened, and cropped in Photoshop (Adobe
)
without changing any speciﬁc feature within.
Pre-embedding electron microscopy
Brains of animals were perfusion ﬁxed with PB containing
4 % formaldehyde and 0.05 % glutaraldehyde. Tissue
blocks were dissected and coronal sections at 60 lm were
sliced with a Vibroslicer (VT1000S; Leica Microsystems).
Immunolabeling for electron microscopy according to the
avidin–biotinylated horseradish peroxidase complex
(ABC) method was performed as described previously
[33]. Brieﬂy, sections were incubated with increasing
gradients of sucrose (5, 10, and 20 %) in PB, ﬂash frozen
on liquid nitrogen, and rapidly thawed in PB to increase
penetration of reagents. Sections were then incubated in
50 mM glycine in Tris-buffered saline (TBS; 50 mM,
0.9 % NaCl, pH 7.4) for 1 h at RT for quenching of free
aldehyde groups, followed by incubation in 10 % NGS and
2 % BSA in TBS for 2 h at RT for blocking of nonspeciﬁc
binding sites. Primary antibodies were then applied for
48 h at 4 C in TBS containing 2 % BSA at a dilution of
2 lg/ml. After washing in TBS, biotinylated secondary
antibodies were applied (1:200 in TBS containing 2 %
BSA, for 24 h at 4 C). Sections were then treated with an
avidin–biotinylated horseradish peroxidase complex (Vec-
tastain
 ABC; 1:100 in TBS, for 3 h at RT). The sections
were reacted with 0.05 % DAB and 0.003 % H2O2 in Tris
buffer (TB; 50 mM, pH 7.4) for 6–7 min at RT, and
washed in TB.
Nanogold silver ampliﬁcation: Alternatively, incubation
with primary antibodies was followed by applying nano-
gold
-conjugated Fab0 fragments (1:100 in TBS). Gold
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using the HQ Silver
TM Enhancement Kit. Sections were
treated with 2 % osmium tetroxide in PB, contrasted by
means of 1 % uranyl acetate in 50 % ethanol, and
embedded in epoxy resin (Durcupan
 ACM Fluca). Serial
sections (70–80 nm) were collected on formvar-coated
copper slot grids. Control experiments included pre-
embedding immunoelectron microscopy for aSYN in brain
slices of wild-type C57Bl/6 mice or veriﬁcation of the
speciﬁcity of the immunostainings by omitting the primary
antibody. Sections were examined in a Philips CM120
TEM, equipped with a Morada CCD camera (Soft Imaging
Systems). Whole images were level-adjusted, sharpened,
and cropped in Photoshop (Adobe
) without changing any
speciﬁc feature within.
Measurement of proteasome activity
The measurement of proteasome activity was performed as
previously described [43]. Brain tissue was homogenized
by sonication in ice-cold PBS (pH 7.4) and protein con-
centration was determined by bicinchoninic acid (BCA)
protein assay (Sigma, St. Louis, MO) according to a stan-
dard protocol. Brain homogenates (100 lg protein) were
incubated in Eppendorf tubes with 100 mM Tris–HCl (pH
7.5), 2 mM CaCl2, 1 mM ATP, and 5 lM ﬂuorogenic
substrate III (Suc-LLVY-AMC, Calbiochem, Darmstadt,
Germany) or substrate IV (Z-VKM-AMC, Calbiochem,
Darmstadt, Germany) up to a total volume of 250 ll. The
tubes were incubated at 37 C for 3 h and the ﬂuorescence
was counted in black 96-well plate in a Beckman Coulter
ﬂuorescence reader at excitation 360 nm and emission
465 nm. Assay buffer without brain extract served as a
background control. To control for sensitivity and speci-
ﬁcity of the Z-Ile-Glu(OtBu)-Ala-Leu-CHO-induced
proteasome inhibition in vitro, 100 lM of Z-Ile-
Glu(OtBu)-Ala-Leu-CHO was added to the assay of con-
trol mouse brain homogenate (100 lg) as stated above and
further reported as ‘‘in vitro assay’’.
Immunoblotting
For protein analysis mice were anesthetized with thiopen-
tal, perfused intracardially with PBS, and brains were
quickly removed, snap frozen in liquid nitrogen, and ﬁnally
stored at -80 C. Probes were homogenized on ice in lysis
buffer containing Complete Mini Protease Inhibitor
Cocktail (Roche Applied Science, Indianapolis, IN), pro-
tein concentration was measured by BCA protein assay
(Sigma, St. Louis, MO), and aliquots for further analysis
were stored at -80 C. Protein balanced samples (30 lg
each) were separated in 10 % SDS–polyacrylamide gels
(Novex, San Diego, CA) and electrotransferred to
nitrocellulose membranes (Hybond-C, Amersham, Buck-
inghamshire, UK). Blots were blocked for 1 h with 2 %
milk powder in PBS containing 0.05 % Tween-20. Primary
antibody incubations were performed overnight at 4 C
followed by 60 min incubation with the appropriate sec-
ondary antibody [ECL anti-mouse IgG and anti-rabbit IgG,
horseradish peroxidase linked (GE Healthcare, Bucking-
hamshire, UK)]. Detection with enhanced chemo
luminescence reagent (ECL; Amersham Pharmacia Bio-
tech) was used. Films were scanned into tif format using an
Epson Perfection 1640SU ﬂatbed scanner, and images were
analyzed and quantiﬁed with ImageJ software. Relative
intensity was determined as the ratio between sample value
measured and standard actin value on the same membrane.
Behavioral tests
Open ﬁeld activity
To test the locomotor activity of the mice we applied the
Flex Field Activity System (San Diego Instruments, San
Diego, California), which allows monitoring and real-time
counting of horizontal and vertical locomotor activity by
544 photo-beam channels. Mice were placed in the center
of the open ﬁeld (40.5 9 40.5 9 36.5 cm) and tested for a
15-min period always at the same time of the day (5:00
p.m.). The tests were performed in a dark room that was
completely isolated from external noises and light during
the test period. The sum of counts in the horizontal and
vertical plane was deﬁned and used for further analysis.
Stride length analysis
The stride length was measured applying the DigiGait
TM
Analysis System (Mouse Speciﬁcs, Quincy, MA) as pre-
viously described [2]. Mice were placed on a transparent
motor-driven treadmill belt and the gait was recorded with
a high-speed digital video camera placed below the belt
(speed 25 cm/s). The collected images were analyzed with
the speciﬁc DigiGait Software 9.0 (Mouse Speciﬁcs,
Quincy, MA) and the mean stride length was determined.
Image analysis
Unbiasedstereologicalanalysiswasperformedaspreviously
described [25]. The numbers of dopaminergic neurons in
substantia nigra pars compacta (SNc), DARPP-32-positive
neurons in striatum and nucleus accumbens, CV-stained
neurons in pontine nuclei, deep cerebellar nuclei, and infe-
rior olive were estimated by an optical fractionator (Nikon
E-800 microscope, Nikon digital camera DXM 1200; Ste-
reo Investigator Software, MicroBrightField Europe e.K.,
Magdeburg, Germany). DARPP-32-stained Purkinje cells
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cell layer [11]. Gliosis was measured by determining mean
gray values of GFAP and CD11b immunoreactivity in stri-
atum, corpus callosum, substantia nigra, cerebellum, and
brain stem at constant acquisition camera settings with val-
ues of 0 for black and 256 for white. Next, optical density
(OD) was obtained after a transformation of mean gray
values by using the formula OD =- log (mean gray/256)
[42].
TEM images of transversely cut, myelinated axons were
taken by means of a Morada CCD camera (Soft Imaging
Systems) linked to a Philips CM120 TEM at a magniﬁca-
tion of 925,000. The axon diameter was measured using
the software iTEM CE (Olympus Soft Imaging Solutions),
and the minimal axon diameter of each axonal proﬁle was
used for further analysis. The numerical ratio between the
diameter of the axon proper and the outer diameter of
the myelinated ﬁber is termed the g-ratio and an increase
in the g-ratio reﬂects a reduced amount of myelination
[27]. The g-ratio was determined in SNc and cerebellum of
both PSI- and vehicle-treated mice by analyzing 100 axons
of approximately 1-lm diameter in each region.
The density of aSYN immunostaining was assessed in
oligodendroglia at the level of the soma (n = 20 cells per
group) using the software iTEM CE (Olympus Soft
Imaging Solutions). Sixteen-bit images of the area of
interest were acquired by means of a Morada CCD camera
(Soft Imaging Systems, Mu ¨nster, Germany) linked to a
Philips CM120 TEM at a magniﬁcation of 911,500 on two
consecutive sections per cell. Four gray value measure-
ments of DAB-immunoperoxidase reactions were taken per
image along the gray scale and the mean gray value was
calculated for each cell. Intensity values representing the
‘‘black’’ (equivalent to gray value 4,600) and ‘‘incident’’
levels (equivalent to gray value 8,500) were calibrated to
the images before measurement. The OD was then calcu-
lated per cell according to the formula OD =- log (gray
value measured/maximum gray value) as done before [16].
The mean OD of aSYN DAB-immunoperoxidase reaction
for all cells within a group is ﬁnally presented as a per-
centage of the maximal OD within the calibrated range of
ODmin = 0.89 (incident light) and ODmax = 1.15 (maxi-
mum reaction product).
Statistics
Results are shown as the mean ± SEM, as indicated in
each ﬁgure. Repeated measures two-way analysis of vari-
ance (ANOVA) was used to compare vehicle- and PSI-
treated wild-type and transgenic mice 2 and 12 weeks after
the ﬁrst injection. For comparison of g-ratios two-way
ANOVA with factors treatment (PSI or vehicle) and region
(SNc or cerebellum) was performed. Post-hoc Bonferroni’s
test was applied where appropriate. p\0.05 was used to
determine statistical signiﬁcance.
Results
Proteasome inhibition in PLP-haSYN transgenic
mice leads to motor impairment
As previously reported transgenic PLP-haSYN mice
showed shortened stride length as compared to age-mat-
ched wild-type mice (p\0.01, Supplementary Table S1).
DigiGait
TM test revealed no further effect of PSI treatment
on the stride length of neither wild-type nor transgenic
mice as compared to vehicle-treated mice (Supplementary
Table S1). Open ﬁeld analysis detected no effect of PSI
treatment in wild-type mice, but showed motor disability
measured by reduction of the horizontal activity of PSI-
treated compared to vehicle-treated PLP-haSYN transgenic
mice 2 weeks after treatment, which was still observed
12 weeks after treatment (Fig. 1a). Additionally, at the late
test point PSI-treated transgenic mice showed signiﬁcant
reduction of rearing behavior (Fig. 1b). PSI-treated trans-
genic mice showed signiﬁcantly reduced open ﬁeld motor
activity as compared to PSI-treated wild-type age-matched
control mice (Fig. 1a, b).
Proteasome inhibition in PLP-haSYN transgenic
mice leads to progressive neurodegeneration in selected
brain areas
Systemic PSI treatment of aged wild-type mice had no
effect on the number of neurons in any of the regions
studied as compared to vehicle-treated animals (Figs. 2, 3).
PSI treatment in transgenic mice with oligodendroglial
aSYN overexpression induced progressive loss of dopa-
minergic neurons in SNc compared to vehicle-treated
transgenic animals or PSI-treated wild-type age-matched
controls (Fig. 2a). PSI-induced loss of dopaminergic neu-
rons in PLP-haSYN transgenic mice was detectable
2 weeks after treatment (28 %) and progressed up to 54 %
neuronal loss at 12 weeks. DARPP-32 positive medium
spiny neurons in the transgenic striatum showed signiﬁcant
reduction as a result of PSI treatment detectable 2 weeks
and 12 weeks after treatment without progression between
weeks 2 and 12 (Fig. 2b). Furthermore, PSI-treated trans-
genic mice showed signiﬁcantly lower number of DARPP-
32-positive striatal neurons as compared to PSI-treated
wild-type mice (Fig. 2b). At the same time DARPP-32
positive neurons in transgenic nucleus accumbens were not
affected by the PSI treatment at any of the time points
studied (Fig. 2c).
Acta Neuropathol (2012) 124:51–65 55
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tex was induced early after PSI treatment in transgenic
PLP-haSYN mice and persisted without further progres-
sion at 12 weeks after treatment (Fig. 3a). PSI-treated
transgenic mice showed signiﬁcantly reduced numbers of
Purkinje neurons as compared to PSI-treated wild-type
mice (Fig. 3a). In parallel, there was progressive loss of
neurons in the inferior olivary complex (Fig. 3c) and the
pontine nuclei in transgenic mice (Fig. 3d), whereas
neurons in the deep cerebellar nuclei were not affected by
the PSI treatment at any of the time points studied
(Fig. 3b).
To deﬁne the contribution of gliosis to the observed PSI-
induced neurodegeneration in the PLP-haSYN transgenic
mice, the optical density of microglial (CD11b) and
astroglial (GFAP) markers was measured in ﬁve different
brain regions. No signiﬁcant difference in the optical
density of CD11b and GFAP immunostaining was found
between vehicle- and PSI-treated transgenic mice, 2 and
12 weeks after treatment (Supplementary Fig. S1).
Reduced brain proteasome activity by PSI treatment
in PLP-haSYN transgenic mice is associated with high
molecular weight ubiquitin accumulation
but no signiﬁcant change of autophagy
The proteasome activity was signiﬁcantly reduced in brains
of PSI-treated PLP-haSYN transgenic mice as measured
with two different ﬂuorogenic chymotrypsin substrates
2 days after completing the PSI application (Fig. 4a, b). At
the same time point PSI treatment had no effect on brain
proteasome activity in wild-type mice supporting data from
previous studies (Supplementary Table S2). In respect to
these results we identiﬁed increased accumulation of high
molecular weight ubiquitinated protein species in the
brains of transgenic but not in wild-type mice treated with
PSI (Fig. 4c). Because a potential crosstalk between the
two degradation pathways, the ubiquitin–proteasome sys-
tem and the autophagy–lysosomal pathway, has been
suggested, we measured the levels of LC3B II, a classical
marker of autophagosome formation. PLP-haSYN trans-
genic mice showed signiﬁcantly increased LC3B II/actin
ratios in the brain as compared to wild-type age-matched
mice possibly reﬂecting increased level of autophagy due
to transgenic haSYN overexpression; however, PSI treat-
ment had no further effect on this ratio either in transgenic
or in wild-type mice (Fig. 4d). Twelve weeks after sys-
temic treatment with the reversible proteasome inhibitor
Z-Ile-Glu(OtBu)-Ala-Leu-CHO no signiﬁcant changes in
the brain proteasome activity were detectable either in
PLP-haSYN transgenic mice (with substrate III:
86.8 ± 1.3 % of baseline; with substrate IV: 91.4 ± 0.8 %
of baseline, for all n = 3), or in wild-type controls (with
substrate III: 116.8 ± 3.4 % of baseline; with substrate IV:
103.6 ± 6.0 % of baseline, for all n = 3).
Ultrastructural analysis of the effects of systemic PSI
treatment in the brain of PLP-haSYN transgenic mice
In light of the effects of PSI on the motor behavior and the
integrity of the striatonigral and olivopontocerebellar sys-
tem in PLP-haSYN transgenic mice along with a transient
inhibition of the proteasome activity in the brain, we ana-
lyzed the ultrastructure of cellular proﬁles in SNc,
cerebellum, and brain stem of PLP-haSYN transgenic mice
12 weeks after PSI or vehicle treatment. In vehicle-treated
PLP-haSYN transgenic mice, signs of degeneration were
mild. Myelinated axons were regular in shape, size, and
density, and just infrequently, distortions of the axon–glia
interface and unusual enlargements of extracellular space
were observed. Otherwise, myelinated axons appeared
smooth and intact (Fig. 5a). Following PSI treatment of
PLP-haSYN transgenic mice, numerous signs of tissue
damage were observed, ranging from cell disassembly to
Fig. 1 Effects of PSI treatment on motor behavior. a Horizontal
open ﬁeld activity showed signiﬁcant decrease 2 weeks after PSI
treatment and remained lower than in vehicle-treated transgenic
animals after 12 weeks. b Vertical activity (rearing) in an open ﬁeld
arena was still preserved 2 weeks after PSI treatment in tg mice but
showed signiﬁcant decline after 12 weeks as compared to vehicle-
treated tg mice. Data, presented here as mean ± SEM, underwent
repeated measures two-way ANOVA followed by Bonferroni’s post-
hoc test. tg vehicle versus tg PSI:
§p\0.05;
§§p\0.01; wt PSI
versus tg PSI: *p\0.05; ***p\0.001. tg transgenic mice, wt wild-
type mice
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123distortions in the ﬁne structure such as thinning of axonal
myelin sheath (Fig. 5b). In order to provide an estimate for
the thickness of the myelin sheath, we calculated the
g-ratio of myelinated axons in SNc and cerebellum of PLP-
haSYN transgenic mice upon PSI or vehicle treatment. In
both areas, the myelin sheath was thinned upon PSI treat-
ment as measured by signiﬁcant increase in the g-ratio
(pSNc\0.001; pcerebellum\0.001; for all n = 100;
Fig. 5c). Myelinated axons also showed other signs of
degeneration in all areas investigated. Mild forms of
degeneration included undulated and split myelin lamellae
and enlargement of the inner oligodendrocytic tongue with
membranous inclusions and irregular vacuolar proﬁles
(Fig. 5d). More pronounced signs of degeneration were
dilated myelin sheaths with split, thinned myelin lamellae
giving rise to broad areas occupied by ﬁbrillary inclusions.
The axoplasm often appeared darkened and amorphous
(Fig. 5e). Sometimes, myelin sheaths were so aberrantly
dilated that a wide space in between the split myelin
lamellae was formed making room for extensive deposition
Fig. 2 Degeneration in the striatonigral system induced by PSI
treatment of PLP-haSYN mice. a The stereologically estimated total
number of dopaminergic neurons (detected by TH immunohisto-
chemistry, see right panel, scale bar 150 lm, inset scale bar 500 lm)
showed signiﬁcant decrease in PSI-treated transgenic (tg) mice
2 weeks after treatment, which progressed further after 12 weeks. No
effect of PSI treatment was detected in wild-type (wt) mice. b Loss of
DARPP-32-positive medium spiny neurons in the striatum (see right
panel, scale bar 100 lm, inset scale bar 500 lm) was induced by PSI
treatment in tg mice as analyzed 2 weeks after treatment and
preserved after 12 weeks without further progression of neurodegen-
eration. No effect of PSI treatment was detected in wt mice. c In
contrast to striatal DARPP-32-positive neurons, DARPP-32-immu-
noreactive neurons in nucleus accumbens of tg mice were not affected
by PSI treatment at any of the time points studied. Data are presented
as mean ± SEM. In all tg groups n = 6, in all wt groups n = 3. Data
were analyzed by repeated measures two-way ANOVA with post-hoc
Bonferroni’s test. tg vehicle versus tg PSI:
§§p\0.01;
§§§p\0.001;
wt PSI versus tg PSI: **p\0.01; ***p\0.001; tg PSI 2 weeks
versus tg PSI 12 weeks:
#p\0.05
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123of ﬁbrillary material (Fig. 5f). Other signs of axonal
degeneration in axonal ﬁbers were irregular, tubular pro-
ﬁles in the axoplasm (Fig. 5g) and enlarged mitochondria
(Fig. 5i). Also at the axon terminals, severe signs of
degeneration were observed. These comprised irregular
vacuolization and undulation of the axonal plasma mem-
brane (Fig. 5h). Other forms of neuronal degeneration
included accumulation of disordered, tubular structures and
amorphous, electron dense material between the tubules or
irregular vacuoles in non-myelinated (Fig. 5l, m) and
myelinated dystrophic neurites (Fig. 5n). Such degenerat-
ing neuronal elements were abundant in PSI-treated PLP-
haSYN transgenic mice but rarely seen in vehicle-treated
transgenic mice. We also analyzed the morphology of
blood vessels in PLP-haSYN transgenic mice compared to
control animals with and without PSI treatment, focusing
on capillaries (Fig. 5j, k). We did not see distinct changes
in their ultrastructure despite a tendency for thinning of the
capillary wall formed by endothelial cells in PLP-haSYN
transgenic mice (Fig. 5k) compared to control animals
(Fig. 5j). Nucleus of endothelial cells and subcellular
organelles such as mitochondria or Golgi apparatus
appeared normal.
Pre-embedding immunoelectron microscopy (IEM) was
used then to deﬁne the subcellular localization of both
transgenic (human) and endogenous (mouse) aSYN in the
brains of transgenic MSA mice 12 weeks after treatment
with PSI or vehicle. PSI treatment induced increased
immunoreactivity for transgenic haSYN in oligodendrog-
lial cytoplasm in immunoperoxidase labelings (Fig. 6a–c).
OD of oligodendroglial aSYN immunoreaction showed
about 25 % increase upon PSI treatment (ODPSI
46.06 ± 5.75 % vs. ODvehicle 20.94 ± 6.14 %). Immuno-
metal labeling (nanogold plus silver ampliﬁcation) for
transgenic haSYN showed different degrees of accumula-
tion of grains at the border between the axolemma and the
myelin sheath within the inner oligodendrocyte tongue, up
to formation of large inclusions of ﬁbrillar haSYN
(Fig. 6d–h) which were rarely seen in vehicle-treated PLP-
haSYN transgenic mice. Immunolabeled endogenous
mouse aSYN (but not haSYN) was detected accumulating
in the cytoplasm of neuronal perikarya and neurites often in
association with lysosomes in PSI-treated mice; however,
formation of aSYN ﬁbrils and ﬁbrillar inclusions in the
neuronal/axonal cytoplasm under PSI treatment was not
observed in any of the studied regions (Fig. 6i–k).
Fig. 3 PSI induced degeneration in the olivopontocerebellar system
of PLP-haSYN transgenic mice. a Purkinje neurons (visualized by
DARPP-32 immunohistochemistry, see right panel, scale bar
200 lm) showed signiﬁcant decrease in PSI-treated transgenic (tg)
mice 2 weeks after treatment, which was further preserved after
12 weeks. No effect of PSI treatment was detected in wild-type (wt)
mice. b No effect of PSI treatment on the number of neurons was
detected in the deep cerebellar nuclei of tg mice (analyzed in CV-
stained sections, right panel, scale bar 200 lm). c Loss of neurons in
the inferior olives of tg mice (see right panel, CV staining, scale bar
400 lm) was induced by PSI treatment, detectable after 12 weeks, but
not after 2 weeks of treatment. No effect of PSI treatment was
detected in wt mice. d The number of neurons in the pontine nuclei
(see right panel, CV staining, scale bar 200 lm) was decreased upon
PSI treatment of tg mice detectable after 12 weeks. No effect of PSI
treatment was detected in wt mice. Data are presented as mean ±
SEM. In all tg groups n = 6, in all wt groups n = 3. Data were
analyzed by repeated measures two-way ANOVA with post-hoc
Bonferroni’s test. tg vehicle versus tg PSI:
§§p\0.01;
§§§p\0.001;
wt PSI versus tg PSI: *p\0.05; **p\0.01; ***p\0.001; tg PSI
2 weeks versus tg PSI 12 weeks:
#p\0.05
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Genetic and pathological studies suggest a role of proteo-
lytic stress in MSA [5, 20]. The current study provides
experimental evidence for possible mechanisms of pro-
gressive MSA-like neurodegeneration resulting from
enhanced proteolytic stress related to systemic proteasome
inhibition and oligodendroglial a-synucleinopathy. Sys-
temic administration of PSI in PLP-haSYN transgenic
mice featuring GCI-like pathology induced motor disabil-
ity associated with selective SND and OPCA. Areas
uninvolved in the human disease such as deep cerebellar
nuclei and nucleus accumbens appeared resistant to PSI
treatment in the transgenic mouse model. The PSI-induced
neuronal loss in PLP-haSYN transgenic mice was
accompanied by accumulation of high molecular weight
ubiquitin conjugates in the brain as well as enhanced
haSYN ﬁbril aggregation in the cytoplasm of oligoden-
droglial cells up to the inner oligodendrocyte tongue, which
led to myelin sheath disruption. Axonal degeneration was
associated with signs of mitochondrial stress in the affected
neurites as evidenced by enlarged or disrupted mitochon-
dria, as well as dysfunctional axonal transport evidenced by
signs of axonal swelling.
Controversial results exist regarding the propensity of
systemic proteasome inhibition to induce PD-like nigral
degeneration in rats [18, 24, 26, 34, 46]. Systemic appli-
cation of proteasome inhibitors has failed to cause any
Fig. 4 Effects of systemic PSI treatment on the ubiquitin–protea-
some system and the autophagy–lysosomal pathway in the brain.
a Proteasome activity given as a percentage of baseline ﬂuorescence
of substrate III (Suc-LLVY-AMC) was reduced by about 93 % after
in vitro application of PSI (in vitro assay) and reduced by about 50 %
after in vivo application of PSI in transgenic (tg) mice at 2 weeks
after ﬁrst intoxication. However, no effect of PSI treatment on brain
proteasome activity was measured at the same time point in wild-type
(wt) mice. b Proteasome activity given as a percentage of baseline
ﬂuorescence of substrate IV (Z-VKM-AMC) was reduced by about
61 % after in vitro application of PSI (in vitro assay) and reduced by
about 50 % after in vivo application of PSI in tg mice at 2 weeks after
ﬁrst intoxication. No effect of in vivo PSI treatment on brain
proteasome activity was measured in wt mice at the same time point.
c Representative immunoblot showing levels of polyubiquitinated
high molecular weight (HMW) species as well as densitometric
analysis of HMW ubiquitin smear (100–250 kDa) in all mouse groups
presented as relative intensity to actin. d Representative immunoblot
showing levels of LC3B I (16 kDa) and LC3B II (14 kDa) as well as
densitometric analysis of LC3B II in all mouse groups presented as
relative intensity to actin. Data are presented as mean ± SEM. In all
cases n = 3. Data were analyzed by two-way ANOVA with post-hoc
Bonferroni’s test. *p\0.05; **p\0.01; ***p\0.001
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123detectable behavioral or neuropathological abnormalities
relevant to PD in mice [4, 19, 36]. In agreement with these
ﬁndings we did not observe signs of motor deterioration
and neuronal loss in striatonigral and olivopontocerebellar
structures upon systemic PSI treatment in wild-type mice.
Further, we showed that systemic PSI treatment fails to
induce suppression of proteasome activity in the brain of
wild-type mice but can reduce transiently up to 50 % the
brain proteasome activity in transgenic PLP-haSYN mice.
Differences in the blood–brain barrier permeability
between wild-type and transgenic mice may contribute to
the observed divergent effects of systemic PSI treatment in
wild-type and transgenic mice. At the ultrastructural level,
we evidenced normal vasculature with intact endothelial
and smooth muscle cells, and regular basal laminae. In case
of capillaries, a tendency for thinning of the endothelial
wall was observed while endothelial junctions and zonulae
occludentes appeared normal. However, physiological and
biochemical modiﬁcations at the level of endothelial cells
and the perivascular glia, such as astrocytic end-feet, might
also induce functional alterations of the blood–brain barrier
and relate to the overexpression of aSYN but this would
need further detailed analysis. Alternatively, the duration
of reduction of brain proteasome activity under systemic
treatment with the reversible proteasome inhibitor Z-Ile-
Glu(OtBu)-Ala-Leu-CHO may differ between wild-type
60 Acta Neuropathol (2012) 124:51–65
123and transgenic mice, which may contribute to the observed
differences in the levels of proteasome activity between the
genotypes analyzed in this study.
Intriguingly, systemic PSI application in the PLP-
haSYN transgenic mouse resulted in selective SND and
OPCA with preservation of neighboring brain structures
like nucleus accumbens or deep cerebellar nuclei, which
are classically spared also in the human disease, MSA.
Although the systemic treatment with the reversible pro-
teasome inhibitor Z-Ile-Glu(OtBu)-Ala-Leu-CHO in PLP-
haSYN transgenic mice had only a transient effect on the
brain proteasome activity, neurodegeneration showed pro-
gression over an observation period of 3 months with early
neuronal loss in SNc, striatum, and cerebellar cortex, which
later on extended to the pontine nuclei and the inferior
olives as well as being signiﬁcantly progressed further in
the SNc. The neuropathology was reﬂected by the motor
phenotype which was characterized by early disability
measured by the open ﬁeld activity test, providing an early
sign of basal ganglia dysfunction. Shortened stride length
was found to be an early sign of motor disability in the
PLP-haSYN transgenic mice [38] correlating with the loss
of dopaminergic neurons in SNc. The current study con-
ﬁrmed the ﬁnding of shortened stride length in PLP-
haSYN transgenic mice versus wild-type aged-matched
controls. However, the stride length test failed to show
further deterioration as a result of the proteolytic stress in
wild-type or PLP-haSYN transgenic mice over 12 months
of age, suggesting that shortening of the stride length may
reﬂect nigral neuronal loss up to a certain degree without
registering further progression, indicating a certain limita-
tion of the test.
Because the origin of aSYN in oligodendrocytes in
MSA brains is still unclear, the transgenic targeted over-
expression of the protein in mouse oligodendroglia
therefore provides a mechanistic tool to replicate this
critical early event in the disease pathogenesis. At baseline
aged PLP-haSYN transgenic mice show a mild phenotype
with (1) insoluble aSYN accumulation in oligodendroglia
only rarely forming b-sheet ﬁbrils [14], (2) nigral dopa-
minergic and brainstem cholinergic neuronal loss [38, 41],
and (3) progressive microglial activation [39]. The addi-
tional transient exogenous proteolytic stress by systemic
application of PSI in these transgenic mice triggers pro-
gressive selective neurodegeneration of MSA type
(Supplementary Table S3) including SND and OPCA
associated with motor deterioration. However, we did not
identify further increase of microglial and astroglial acti-
vation in the degenerating regions at the time points studied
in the PLP-haSYN transgenic mice. Additional studies
may be needed for evaluation of changes in the glial
activation proﬁles. However, one may argue that reactive
gliosis and neuroinﬂammatory response appear temporarily
within the period between the two test time points and has
not been detected with the used protocol. Alternatively,
Middeldorp et al. [28] demonstrate that proteasome
inhibitors may reduce GFAP expression in a model of
induced astrogliosis in vivo, whereas Elliott et al. [7]
provide evidence of the anti-inﬂammatory properties of
proteasome inhibitors. Taken together, these data may
suggest an explanation of the lack of further astroglial and
microglial activation in the presence of severe PSI-induced
neurodegeneration in the PLP-haSYN transgenic mouse
model of MSA. If so, non-inﬂammatory mechanisms may
be the leading pathogenic players of MSA-like neurode-
generation in the PSI-induced transgenic model.
Detailed ultrastructural analysis revealed speciﬁc ﬁne
structure changes related to the progressive neurodegen-
eration in PLP-haSYN transgenic mice following the
transient suppression of brain proteasome activity [29]. No
Lewy bodies/neuronal ﬁbrillar aSYN inclusions were
observed in neurons of the PLP-haSYN transgenic mice
Fig. 5 Ultrastructural characterization of the effects of PSI treatment
in PLP-haSYN transgenic mice 12 weeks after ﬁrst intoxication. a In
SNc of vehicle-treated animals, signs of degeneration are mild and
myelinated axons of regular shape and size are observed. Infre-
quently, distortions of the axon–glia interface and enlarged
extracellular spaces are seen. b Upon PSI treatment, numerous signs
of tissue damage arise, such as thinning of the myelin sheath, tissue
disruption, distortions of the axon–glia interface, and membrane
splitting. c Calculating the g-ratio conﬁrms thinning of the myelin
sheath to a signiﬁcant extent, both in SNc and the alveus of the
cerebellum of PLP-haSYN transgenic mice upon PSI treatment. d In
a degenerating axon at an early stage, myelin lamellae are undulated
and detached (asterisks). The inner tongue is enlarged and shows
membranous inclusions and vacuolar proﬁles (arrows). The axoplasm
appears normal and intact. e In some cases, signs of axonal
degeneration are more pronounced with thinned and dilated myelin
(arrowheads), and split lamellae giving rise to an open space
displaying scattered, ﬁbrillary inclusions (asterisks). Parts of the
axoplasm are darkened and amorphous. f At a state of pronounced
degeneration, a wide area is formed in between split lamellae, which
is occupied by ﬁbrillary inclusions (asterisks). g In some axons, the
myelin sheath appears normal despite mild forms of membrane
splitting (arrowheads), but the axoplasm is occupied by irregular,
tubular proﬁles to a large extent (arrows), possibly representing
beginning of axonal swelling. h A degenerating axon terminal,
synapsing with a small dendritic spine, displays signs of vacuolization
and an undulated plasma membrane (arrows). i The myelin sheath of
this axon is thinned and the mitochondrium is unusually enlarged. j A
capillary in the cerebellum of a control wild-type animal displays
regular structure with a normal endothelial cell, basal lamina, and
perivascular glia. k In comparison, the endothelial wall of a capillary
in the cerebellum of a PLP-haSYN mouse is thinned. l, m Some non-
myelinated dystrophic neurites display abnormal accumulation of
tubular and irregular vacuolar proﬁles within dark amorphous
material, accompanied by undulation of the outer membrane
(arrows). n A dystrophic neurite with a thin myelin sheath (arrow-
heads) shows abnormal tubular proﬁles, and mitochondria are
aggregated in the remainder of the cytoplasm. At axon terminal, Cb
cerebellum, End endothelial cell, M mitochondrium, Nuc nucleus,
SNc substantia nigra pars compacta, Sp spine. Scale bars 1.5 lmi na,
b, j, k; 700 nm in d, i; 500 nm in e;1lmi nf, l, m, n; 600 nm in g, h
b
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123Fig. 6 Immunolocalization of transgenic haSYN and endogenous
mouseaSYNbypre-embeddingelectronmicroscopyintissuesamplesof
vehicle-and PSI-treatedPLP-haSYNtransgenic mice. a Inthealveusof
the cerebellum of a vehicle-treated animal, the perikaryon of an
oligodendrocyte is exclusively labeled for transgenic haSYN with a
15G7 antibody applying an immunoperoxidase reaction technique,
which yieldsanelectron-opaque reactionproduct.The cytoplasm shows
patchy 15G7 immunolabeling, the nucleus and cytoplasmic organelles
such as mitochondria are free of immunolabeling. Surrounding axonal
and glial proﬁle without signs of degeneration are immunonegative.
b Thesamestainingpatternisobservedinacerebellartissuesampleofa
PSI-treatedanimal,butthecytoplasmoftheoligodendrocyteisuniformly
labeled and the density of the immunostaining is markedly enhanced.
c Subcellular organelles such as mitochondria and the nucleus are
immunonegative,shownforacerebellaroligodendrocyteofaPSI-treated
animal at higher magniﬁcation. Surrounding neuronal and glial proﬁles
are not labeled. d Using an immunometal labeling technique, scattered
immunoparticles localizing haSYN (arrowheads) are abundant in the
interface between the axoplasm and the myelin sheath in a myelinated
axon of the cerebellum of a PSI-treated animal, most likely representing
haSYN localization to the inner tongue of the oligodendrocytic process.
Myelin lamellae and the axoplasm are free of any immunolabeling.
Surrounding myelinated axons without clear signs of degeneration are
immunonegative.eThesamestainingpatternisobservedinamyelinated
axon in the SNc of a PSI-treated animal. The axon–myelin interface is
markedly enlarged and haSYN immunoparticles (arrowheads)a r e
denselypackedinthisarea.fInanaspectofalatestatedegeneratingaxon
in the alveus of the cerebellum of a PSI-treated animal, dense haSYN
immunolabeling of ﬁbrils (arrowheads) is apparent in the enlarged area
in between split myelin lamellae (asterisks). g The same localization
p a t t e r no fh aSYN is observed in an aspect of a late state degenerating
axon in the SNc. h Higher magniﬁcation reveals association of haSYN
immunoparticles (arrowheads)w i t hﬁ b r i l so f1 0± 0.4 nm in diameter
(n = 20, measured at a magniﬁcation of 966k in 10 different proﬁles)
loosely arranged in the enlarged area in between split myelin lamellae
(boxed area in g). i Scattered immunoparticles localizing endogenous
mouse aSYN (arrowheads) are observed in the cytoplasm of a dendritic
spine in the SNc of PSI-treated transgenic mouse. The axon terminal
synapsing with this spine, and neighboring tissue elements are immu-
nonegative. Note: Neuronal aSYN immunoreactivity was detected only
with an antibody cross-reacting with mouse aSYN (clone 42), but not
with 15G7 antibody detecting haSYN. j Scattered mouse aSYN
immunoparticles (arrowheads) are observed also in a neuronal soma in
the SNc of a PSI-treated transgenic mouse. Immunoparticles are
aggregated at a lipofuscin granule. k In the same neuron as shown in j,
theveryproximalportionoftheprincipaldendriteisalsodenselylabeled
formouseaSYN.Scatteredimmunoparticlesareseeninthecytoplasmof
the dendritic stem, cytoplasmic organelles such as mitochondria and
endoplasmic reticulum are immunonegative. At axon terminal, Cb
cerebellum, Lf lipofuscin granule, M mitochondrium, SNc substantia
nigraparscompacta.Scalebar1 lmina,c;1.25lminb;400 nmind,e,
i;5 0 0n mi nf, j; 700 nm in g, k; 200 nm in h
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123following PSI treatment. However, PSI treatment resulted
in disturbed degradation of transgenic aSYN in oligoden-
droglia. This was associated with increased intracellular
accumulation of aSYN in oligodendrocytes as measured by
increased OD of aSYN immunoreactivity in oligoden-
droglial cytoplasm similar to previous in vitro observations
[9]. Furthermore, through application of immunometal
labeling, accelerated formation of aSYN ﬁbrils of
approximately 10-nm width was observed in oligodendro-
cytes of PSI-treated PLP-haSYN transgenic mice,
reminiscent of the ultrastructure of GCI core ﬁbrils in
human MSA [10]. With the applied systemic dose of the
reversible proteasome inhibitor Z-Ile-Glu(OtBu)-Ala-Leu-
CHO and after 3 months post-intoxication survival, we
observed ultrastructural signs of signiﬁcant oligodendrog-
lial dysfunction associated with enhanced cytoplasmic
accumulation of aSYN ﬁbrils rather than signs of oligo-
dendroglial cell death as proposed by earlier in vitro studies
in primary PLP-haSYN oligodendroglia [9]. The increased
accumulation of aSYN in oligodendroglial cytoplasm
affected the perinuclear soma and the oligodendroglial
processes up to the inner tongue opposing the axolemma.
The distal accumulation of aSYN ﬁbrils was predomi-
nantly associated with myelin sheath disruption and
thinning of the myelin (measured here by increased
g-ratio), which ﬁnally provided compromised myelin sup-
port to the affected axons.
Axonal degeneration and mitochondrial stress may fol-
low dysmyelination after proteolytic stress in PLP-haSYN
transgenic mice, similar to recently proposed mechanisms
in vitro [17]. However, both myelinated and non-myelin-
ated neurites showed signs of degeneration. This ﬁnding
may indicate (1) direct, oligodendroglia-independent
effects of PSI treatment on neurons, or (2) PSI-induced
secondary neurodegeneration due to oligodendroglial dys-
function either related or unrelated to disturbed
myelination. Earlier studies have shown that dysfunction of
the myelinating glia may lead to axonal swelling and
axonal degeneration either uncoupled from the mainte-
nance of compact myelin [21] or associated with defect
myelin wrapping [3]. The possible mechanisms of glial
support of axons are still under debate [31]; however, oli-
godendroglial malfunction seems to be the main operative
pathogenic mechanism in oligodendroglial a-synucleinop-
athy enhanced by PSI treatment in the PLP-haSYN
transgenic mice leading to neurodegeneration of MSA
type. Finally, the axonal degeneration induced by proteo-
lytic stress in PLP-haSYN transgenic mice, which may be
associated with loss of trophic support and axonal main-
tenance provided by oligodendroglia/myelin, is reminiscent
partly of a model of nonimmune-mediated oligodendrocyte
injury [23, 45]. At this stage, the basis of selective vul-
nerability in MSA remains unclear.
Recent observations have suggested distinct roles and
interplay of the ubiquitin–proteasome system and the
autophagy–lysosomal pathway in the degradation of aSYN
under normal conditions or neuronal overexpression of the
protein [6]. Our results suggest a baseline upregulation of
autophagy (increased LC3B II signal as a measure of
autophagosome formation) in PLP-haSYN transgenic
mouse brains related to the overexpression of aSYN in
oligodendroglia in contrast to no change in autophagy rates
upon overexpression of aSYN under the regulatory control
of the platelet-derived growth factor-b (PDGF-b) neuronal
promoter [6]. Furthermore, systemic proteasome inhibition
in the PLP-haSYN transgenic mouse induced accumulation
of poliubiquitinated high molecular weight species similar
to the one observed by topical application of proteasome
inhibitor in PDGF-b-haSYN transgenic mice. Yet, pro-
teasome inhibition in the presence of oligodendroglial
aSYN overexpression had no effect on the rate of
autophagy in contrast to previously reported accelerated
autophagy upon proteasome inhibition in the presence of
neuronal aSYN overexpression [6]. These differences may
reﬂect variable control of both aSYN degradation systems
in neurons and oligodendroglia which may need more
detailed analysis to identify pathogenic variations relevant
to neuronal and oligodendroglial a-synucleinopathies.
In conclusion, the current study provides new evidence
supporting the role of oligodendroglial a-synucleinopathy
in the pathogenesis of MSA [44] and sheds light on the
possible interactions between neurons and dysfunctional
oligodendroglial cells that result in a classical non-
inﬂammatory neurodegenerative disorder associated with
the pathological accumulation of a misfolded protein.
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